A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma

Trial Profile

A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Voxtalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Apr 2017 Results published in the Investigational New Drugs
    • 26 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top